Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.
Pharma IQ takes a look at some of the industry’s most prestigious movers and shakers causing ripples in the market over the last few months. Full Article »
Japanese pharmaceutical giant Eisai has launched a new epilepsy drug in Europe following approval by the European Commission.
Discovered and developed in the United Kingdom, Fycompa® (perampanel) is an important new addition to the treatment of epilepsy in Europe as it has efficacy in difficult-to-treat patients with uncontrolled partial o Full Video »
Diabetes is a global threat. Researchers estimate that 26.6 million people in the Middle East and North Africa currently have diabetes. Six countries in the region are among the top 10 globally with the highest prevalence of diabetes. In this interview Professor Peter Schwarz, Head of Department of Prevention and Care of Diabetes University Full Podcast »
In the last article I looked at the starting point of developing your organisation’s strategy, the legislation and its impact. In this article I discuss defining your solution, what to look for when picking your implementation partners and the key aspects to consider when resourcing the project team. Full Column »
Counterfeit pharmaceuticals can cause a lot of harm – drug recalls, loss of public confidence, law suits, and risks to patient safety. In the combat against malicious tampering, anti-counterfeiting technology aims to prevent the emergence of counterfeit drugs by creating hurdles to deter by making the task of cloning a drug too complex and expensive. Full Whitepaper »